Fig 1: Immunohistochemical analysis of FAT4 in GC patient tissues and Kaplan–Meier survival analysis(A-B) Representative IHC images (100X and 200X) showing positive FAT4 expression in normal gastric epithelium. Scale bar, 100 μm. (C-D) Representative IHC images (100X and 200X) showing positive FAT4 expression in GC patient tissue. Scale bar, 100 μm. (E-F) Representative IHC images (100X and 200X) showing negative FAT4 expression in GC patient tissue. Scale bar, 100 μm. (G-H) Representative IHC images (100X and 200X) showing negative FAT4 expression in liver metastatic tissue from GC patients. Scale bar, 100 μm. (I-J) Representative IHC images (100X and 200X) showing negative FAT4 expression in ovarian metastatic tissue from GC patients. Scale bar, 100 μm. (K) Kaplan–Meier analysis showing survival curves of GC patients (n=449) with high (red) or low/no (green) FAT4 expression Note:* denotes P<0.05 compared to high FAT4 expressing GC patients. (L) qRT-PCR analysis of FAT4 mRNA expression in 173 paired GC and adjacent noncancerous patient tissue samples. FAT4 was down-regulated in the tumors than adjacent noncancerous tissues (n=173, P<0.05). We classified the patient samples (n=179) based on lymph node and distant metastases status into three groups namely, group1 (N0, M0, n=50), group 2 (N>1, M0, n=64) and group 3 (N>1, M1, n=59). There is no difference of FAT4 expression between cancer tissue and adjacent noncancerous tissues in group1 and group2 (P>0.05), but in group3 the FAT4 expression in cancer tissue is significant lower than adjacent noncancerous tissues (P<0.05). FAT4 expression was significant lower in cancer tissues from group 2 and group3 patients than group 1 patients (P<0.05).
Fig 2: Effect of FAT4 silencing on cell proliferation, migration and invasion of GC cells by MTT, wound healing and Transwell migration and invasion assays(A) MTT assay showing cell proliferation rates of BGC-823-FAT4-KO and BGC-823-shFAT4 cells and their corresponding controls, BGC-823-KO-NC and BGC-823-shNC cells. As shown, FAT4 knockdown and knockout cells demonstrate higher proliferation rate than the controls (*P<0.05). (B) Representative images of wound healing assay showing increased migration of BGC-823-FAT4-KO and BGC-823-shFAT4 cells than their corresponding controls, BGC-823-KO-NC and BGC-823-shNC cells. (C) Transwell migration and invasion assays demonstrating increased migration and invasiveness of BGC-823-FAT4-KO and BGC-823-shFAT4 cells than their corresponding controls, BGC-823-KO-NC and BGC-823-shNC cells. Data represent mean ±SD from 3 independent experiments. * denotes P < 0.05 compared to corresponding controls.
Fig 3: Analysis of FAT4 promoter methylation status and its association with GC(A) Schematic representation of the 4.5 kb CpG island region in the human FAT4 gene promoter. (B) The representative picture of the Methylation specific PCR analysis of FAT4 promoter region in GC tissues. The samples Nos. 2, 4 and 11-18 show high FAT4 methylation and Nos. 6, 9, 10 and 32 show low methylation. (C) FAT4 expression levels and methylation specific PCR analysis of FAT4 promoter region in GC cell lines. (D) Kaplan–Meier analysis comparing survival curves of 173 GC patients with and without FAT4 methylation. Patients without FAT4 methylation (red) show increased survival than patients with FAT4 methylation (*P<0.05).
Fig 4: Effect of FAT4 knockout on lung metastasis of GC cells in the nude mice model using PET-CT scans(A) PCT-CT scan analysis showing metastasis status at 5 weeks after tail vein injection of BGC-823-FAT4-KO and BGC-823-KO-NC cells into nude mice. CT scan images (left of A) show tumor nodules in the lungs from BGC-823-FAT4-KO group (indicated by red arrow), whereas tumor nodules are absent or less clearly defined in the lungs of the control group. PET scan image (left central of A) and merge analysis image (right central of A) show higher 18F-FDG activity in the lungs of BGC-823-FAT4-KO group than the BGC-823-KO-NC group (indicated by blue arrows). The lung metastasis histology figures (top right of A) shown fewer number of lung metastasis nodes in BGC-823-KO-NC, but the numbers of lung metastasis nodes are dramatically increased in BGC-823-FAT4-KO (below right of A). (B) Histogram plots show increased number of metastatic tumor nodules in the BGC-823-FAT4-KO group mice (n=5) than BGC-823-KO-NC group (n=5). Data represent mean ± SD from 3 independent experiments. * denotes P < 0.05.
Fig 5: Real time cellular analysis of the effect of FAT4 silencing on GC cell growth, migration and invasion(A) Schematic representation of the sgRNA binding site in FAT4 gene and the FAT4 knock-out model by CRISPR/CAS9 methodology. (B) Real Time Cellular Analysis (RTCA) showing relative cell indices of cellular growth, migration and invasion of BGC-823-FAT4-KO and BGC-823-shFAT4 cells and their corresponding controls, BGC-823-KO-NC and BGC-823-shNC cells. Note:* denotes P<0.05 compared to corresponding controls.
Supplier Page from Novus Biologicals, a Bio-Techne Brand for FAT4 Antibody [FITC]
Available conjugates: Available conjugates: FITC, Alexa Fluor 350, Janelia Fluor 549, DyLight 550, mFluor Violet 500 SESizes Available: 0.1 ml